HomePress-release

Redding, California - November 27, 2024

Viral Vaccines Market to be Worth $64.18 Billion by 2031

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging – Global Forecast to 2031

Meticulous Research^®—a leading market research company, published a research report titled, "Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging – Global Forecast to 2031."

According to this latest publication from Meticulous Research^®, the viral vaccines market is projected to reach $64.18 billion by 2031, at a CAGR of 9.3% from 2024 to 2031. The growth of this market is driven by the increasing government focus on immunization programs, technological advances in vaccine administration, and the use of inactivated vaccines in surgeries and treatments. However, the high costs of vaccine development and the long timelines of vaccine manufacturing restrain the growth of this market.

Furthermore, the growing focus on therapeutic vaccines, this increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to generate growth opportunities for market stakeholders. However, product recalls and inadequate access to vaccines are major challenges impacting the market’s growth.

Key Players

The key players profiled in the viral vaccines market report are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), CSL Limited (Australia), Merck & Co., Inc. (U.S.), Sanofi (France), Sinovac Biotech Ltd. (China), Moderna, Inc. (U.S.), Valneva SE (France), Dynavax Technologies Corporation (U.S.), EMERGENT BIOSOLUTIONS INC. (U.S.), Johnson & Johnson (U.S.), Bharat Biotech Ltd. (India), and Serum Institute of India Pvt. Ltd. (India).

The viral vaccines market is segmented by Form (Liquid Vaccines, Lyophilized Vaccines), Vaccine Type (mRNA Vaccines, Live-attenuated Vaccines, Inactivated Vaccines, Viral Vector Vaccines, Subunit & Conjugate Vaccines, Toxoid Vaccines, Combination Vaccines), Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, and Other Routes of Administration), Approach (Preventive Vaccines, Therapeutic Vaccines), Indication (Influenza, Human Papilloma Virus (HPV), Rotavirus, Poliomyelitis (Polio), Hepatitis, Cancer, and Other Indications), Packaging (Vials, Prefilled Syringes) and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.

Among the forms analyzed in this report, in 2024, the liquid vaccines segment is expected to account for the largest share of the market. Liquid vaccines contain formulations in the liquid form which are easy to administer. This segment’s large market share is driven by factors such as ease of administration, non-requirement of reconstitution, reduced risk of errors, simplified logistics compared to lyophilized vaccines, lower equipment & training requirements, and reduced contamination risks.

Among the vaccine types analyzed in this report, in 2024, the subunit & conjugate vaccines segment is expected to account for the largest share of the market. This segment’s large market share can be attributed to the advantages offered by subunit & conjugate vaccines, such as the absence of live components or microorganisms, the ability to precisely target pathogens, the capacity to elicit a protective immune response, and the low risk of immunogenicity and long-term immunity.

Among the approaches analyzed in this report, in 2024, the preventive vaccines segment is expected to account for the larger share of the market. Preventive vaccines are designed to protect individuals from infections caused by viruses or bacteria. This segment’s large market share can be attributed to the increasing prevalence of chronic and infectious diseases, growing public awareness regarding immunization, and initiatives aimed at promoting vaccination programs.

Among the indications analyzed in this report, the influenza segment is expected to account for the largest share of the market. This segment’s large market share can be attributed to factors such as the vaccines' effectiveness in preventing disease, reducing morbidity and mortality rates, and cost-effectiveness.

Among the packaging types analyzed in this report, the vials segment is expected to account for the largest share of the market. This segment’s large market share can be attributed to the protective environment vials offer, which helps maintain vaccine stability by shielding it from external factors like moisture, light, and contamination. Additionally, vials allow for visual inspection of the vaccine contents before administration and feature tamper-proof packaging, which prevents unauthorized access or tampering.

Among the regions analyzed in this report, in 2024, North America is expected to account for the largest share of the market. North America’s significant market share can be attributed to the region's advanced research infrastructure, the presence of key pharmaceutical companies, collaborations between research institutes and pharmaceutical firms, the establishment of new facilities by major players, heightened awareness of vaccination, and the ongoing risk of emerging pandemics.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5920

Key questions answered in the report-

Which are the high-growth market segments in terms of form, vaccine type, route of administration, approach, indication, and geography?
What was the historical market for viral vaccines across the globe?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, opportunities, and challenges in the viral vaccines market?
Who are the major players operating in the viral vaccines market?
What is the competitive landscape like?
What are the recent developments in the viral vaccines market?
What are the different strategies adopted by the major players in the viral vaccines market?
What are the geographical trends and high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researc

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & WastewaterTechnologies

Miscellaneous / Others

Redding, California - November 27, 2024

Viral Vaccines Market to be Worth $64.18 Billion by 2031

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging – Global Forecast to 2031

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies